Coagulation Parameters in Elderly Patients with Severe Pneumonia: Correlation with Disease Severity and Prognosis

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2025 Jan 22

PMID 39840395

Authors

Qiuyue Zhang

Yingchao Liu

Chuntang Tong

Lina Zhang

Rongchen Li

Wenbin Guo

Jianliang Li

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to investigate the levels of coagulation parameters in elderly patients with severe pneumonia and analyse their correlation with disease severity and prognosis.

Methods: A retrospective study was conducted on 207 elderly patients (aged ≥60 years) with severe pneumonia admitted to our hospital between January 2022 and December 2023. Demographic data, clinical characteristics and coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time and fibrinogen (FIB), were collected. Patients were divided into survivor and non-survivor groups based on 28-day mortality. The differences in coagulation parameters between groups and their correlation with disease severity and prognosis were analysed.

Results: The 28-day mortality rate was 52.2%. Non-survivors had significantly higher PT, APTT and D-dimer levels and lower FIB levels than survivors ( < 0.05). Multivariate logistic regression analysis showed that elevated PT (odds ratio [OR] = 1.218, 95% confidence interval [CI]: 1.076-1.379, = 0.002) and D-dimer (OR = 1.109, 95% CI: 1.032-1.192, = 0.005) were independent risk factors for 28-day mortality. The combined model using PT and D-dimer showed the highest predictive value for 28-day mortality (area under the curve = 0.801, 95% CI: 0.739-0.863, < 0.001), with a sensitivity of 0.759 and specificity of 0.758.

Conclusion: Coagulation dysfunction is common in elderly patients with severe pneumonia. Prothrombin time and D-dimer levels are closely associated with disease severity and can be valuable indicators for predicting prognosis in this population.

References

Meyer N, Gattinoni L, Calfee C . Acute respiratory distress syndrome. Lancet. 2021; 398(10300):622-637. PMC: 8248927. DOI: 10.1016/S0140-6736(21)00439-6. View

Zhao D, Sun Y, Li J, Li X, Ma Y, Cao Z . Effectiveness of inactivated COVID-19 vaccines in preventing COVID-19-related hospitalization during the Omicron BF.7-predominant epidemic wave in Beijing, China: a cohort study. BMC Infect Dis. 2024; 24(1):991. PMC: 11406771. DOI: 10.1186/s12879-024-09889-7. View

Konstantinides S, Meyer G, Becattini C, Bueno H, Geersing G, Harjola V . 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2019; 41(4):543-603. DOI: 10.1093/eurheartj/ehz405. View

van der Poll T, Parker R . Platelet Activation and Endothelial Cell Dysfunction. Crit Care Clin. 2020; 36(2):233-253. DOI: 10.1016/j.ccc.2019.11.002. View

Lim W, van der Eerden M, Laing R, Boersma W, Karalus N, Town G . Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58(5):377-82. PMC: 1746657. DOI: 10.1136/thorax.58.5.377. View

Cilloniz C, Peroni H, Gabarrus A, Garcia-Vidal C, Pericas J, Bermejo-Martin J . Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis. Open Forum Infect Dis. 2021; 8(6):ofab169. PMC: 8231373. DOI: 10.1093/ofid/ofab169. View

Adelborg K, Larsen J, Hvas A . Disseminated intravascular coagulation: epidemiology, biomarkers, and management. Br J Haematol. 2021; 192(5):803-818. DOI: 10.1111/bjh.17172. View

Blanc E, Chaize G, Fievez S, Feger C, Herquelot E, Vainchtock A . The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia. BMC Infect Dis. 2021; 21(1):949. PMC: 8442401. DOI: 10.1186/s12879-021-06669-5. View

Rayes J, Bourne J, Brill A, Watson S . The dual role of platelet-innate immune cell interactions in thrombo-inflammation. Res Pract Thromb Haemost. 2020; 4(1):23-35. PMC: 6971330. DOI: 10.1002/rth2.12266. View

10.

Levi M, van der Poll T . Coagulation and sepsis. Thromb Res. 2016; 149:38-44. DOI: 10.1016/j.thromres.2016.11.007. View

11.

Collins P, Macchiavello L, Lewis S, Macartney N, Saayman A, Luddington R . Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol. 2006; 135(2):220-7. DOI: 10.1111/j.1365-2141.2006.06281.x. View

12.

Zeineddin A, Dong J, Wu F, Terse P, Kozar R . Role of Von Willebrand Factor after Injury: It May Do More Than We Think. Shock. 2020; 55(6):717-722. PMC: 10363401. DOI: 10.1097/SHK.0000000000001690. View

13.

Aliberti S, Dela Cruz C, Amati F, Sotgiu G, Restrepo M . Community-acquired pneumonia. Lancet. 2021; 398(10303):906-919. DOI: 10.1016/S0140-6736(21)00630-9. View

14.

Iba T, Levy J, Warkentin T, Thachil J, van der Poll T, Levi M . Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019; 17(11):1989-1994. DOI: 10.1111/jth.14578. View

15.

Mari D, Coppola R, Provenzano R . Hemostasis factors and aging. Exp Gerontol. 2007; 43(2):66-73. DOI: 10.1016/j.exger.2007.06.014. View

16.

Davalos D, Akassoglou K . Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2011; 34(1):43-62. DOI: 10.1007/s00281-011-0290-8. View

17.

Engelmann B, Massberg S . Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2012; 13(1):34-45. DOI: 10.1038/nri3345. View

18.

Franchini M . Hemostasis and aging. Crit Rev Oncol Hematol. 2006; 60(2):144-51. DOI: 10.1016/j.critrevonc.2006.06.004. View

19.

Tsoumani E, Carter J, Salomonsson S, Stephens J, Bencina G . Clinical, economic, and humanistic burden of community acquired pneumonia in Europe: a systematic literature review. Expert Rev Vaccines. 2023; 22(1):876-884. DOI: 10.1080/14760584.2023.2261785. View

20.

Ocrospoma S, Restrepo M . Severe aspiration pneumonia in the elderly. J Intensive Med. 2024; 4(3):307-317. PMC: 11258512. DOI: 10.1016/j.jointm.2023.12.009. View